Lisata unit Marea Therapeutics doses first patient in Phase 2 acromegaly trial of MAR002

By Public Technologies
  • Marea Therapeutics, a subsidiary of Lisata Therapeutics, dosed the first patient in a Phase 2 trial of MAR002 for acromegaly.
  • MAR002 is an investigational allosteric monoclonal antibody targeting the growth hormone receptor, aimed at suppressing IGF-1.
  • Phase 2 plans to enroll about 72 participants across three dose arms, using a 900 mg loading dose, versus placebo.
  • Primary endpoint is IGF-1 reduction after 10 weeks of treatment; eligible participants can enter an open-label extension.
  • Phase 1 data presented in June 2026 indicated deep, durable IGF-1 suppression, with dosing potentially as infrequent as every two weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839270) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.